Targeted Delivery– tag –
-
Soufflé Therapeutics Initiates Phase I/II Clinical Trial for Muscle-Targeted siRNA Conjugate SFL-0821 in FSHD
allsci.com USA Overview Soufflé Therapeutics has commenced a Phase I/II clinical trial for SFL-0821, a novel antibody-siRNA conjugate designed for patients with Facioscapulohumeral Muscular Dystrophy (FSHD). SFL-0821 specifically targets... -
Unlocking TPD’s Promise: Nanomedicine and Programmable Proximity Platforms Revolutionize Degrader Delivery
MDPI Switzerland Overview Nanomedicine and programmable proximity platforms are emerging as pivotal solutions to the delivery challenges inherent in targeted protein degradation (TPD) technologies. Degrader molecules like PROTACs often f... -
Nanotechnology Overcomes Drug Delivery Challenges: Liposomes & Polymeric Nanoparticles Enhance Drug Solubility and Targeted Delivery
Scientific Review Unknown Overview A recent review highlights nanotechnology's transformative role in overcoming traditional drug delivery challenges, such as poor solubility and non-specific distribution. Diverse nanocarriers, including... -
AusperBio Secures $120M Series C Funding to Advance Phase 3 for Chronic Hepatitis B ASO Therapy AHB-137 and Accelerate Au-HALO™ Platform’s HBV siRNA Development
BioSpace Global Overview AusperBio Therapeutics has successfully completed a $120 million Series C financing round to vigorously advance its lead antisense oligonucleotide (ASO) therapy, AHB-137, through Phase 3 enrollment and towards co... -
Korro Bio Accelerates RNA Editing Platform into Clinic with First-in-Human Trial for Hyperammonemia and Designation of AATD Candidate
GlobeNewswire (via Korro Bio, Inc.) USA Overview Korro Bio has announced plans to initiate first-in-human clinical trials for its hyperammonemia treatment candidate, KRRO-121, in late 2026. Concurrently, the company designated KRRO-111 a... -
ReCode Therapeutics Secures Funding, Partners with Gene Editing Firm to Fast-Track Cystic Fibrosis Gene Therapy with SORT LNP Platform
BioSpace (via Business Wire) USA Overview ReCode Therapeutics has announced new funding from the Cystic Fibrosis Foundation and a strategic partnership with a leading gene editing company. These initiatives will accelerate the developmen... -
Nanomedicine Conquers Glioblastoma’s Blood-Brain Barrier: Revolutionizing Treatment via Targeted Delivery, Stimuli-Responsiveness, and AI
Drug Target Review UK Overview Nanomedicine is emerging as a critical solution to overcome the formidable blood-brain barrier (BBB) in treating glioblastoma (GBM), the most aggressive brain tumor. Researchers are developing advanced nano... -
AI-Powered In Silico Design Revolutionizes RNA-LNP Therapies for Targeted Delivery and CRISPR Gene Editing
InSilicoMinds USA Overview In silico (computational) design is fundamentally transforming the development of lipid nanoparticle (LNP) and RNA therapeutics by enabling the precise optimization of LNP properties for tissue-specific drug de... -
Unlocking mRNA LNP Design: Cholesterol Found Unnecessary for Non-Hepatic Delivery
ACS Nano USA Overview New research thoroughly dissects the functional roles of individual lipid components within mRNA lipid nanoparticles (LNPs), revealing that while ionizable lipids are critical for delivery efficacy, cholesterol is e... -
Comprehensive Guide Published: RNA Therapeutics, from ASO to LNP/GalNAc Platforms, Shaping the Future of Precision Medicine
MDPI International Overview A comprehensive guide published by MDPI overviews the engineering history of RNA therapeutics, spanning from ASOs to modern siRNA and mRNA-LNP-based therapies. It highlights a growing regulatory trend favoring...
